ImmunityBio says ANKTIVA plus BCG shows lower cost per sustained responder vs TAR-200

ImmunityBio Inc

ImmunityBio Inc

IBRX

0.00
  • ImmunityBio reported preliminary results from a health economic analysis that were presented at ISPOR 2026 on May 17-20.
  • The analysis found ANKTIVA with BCG delivered better economic value than TAR-200 in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ, driven by a higher rate of durable responses and fewer bladder removals.
  • Across a three-year Medicare-based model, ANKTIVA with BCG showed lower costs per sustained responder, lower costs tied to avoiding cystectomy, and lower costs per cystectomy-free time than TAR-200.
  • The cost advantage was attributed mainly to lower treatment acquisition and administration costs in the model.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605220730BIZWIRE_USPR_____20260522_BW861965) on May 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.